Skip to main content
Bloomberg Law

How Life Sciences Firms Can Reduce DOJ Enforcement Risks

May 6, 2021
Authors
Jaime L.M. JonesJack W. Pirozzolo

The Anti-Kickback Statute has long been a driver of enforcement actions against the life sciences industry. In this article, Sidley lawyers explore areas that are most likely to draw enforcement scrutiny and how compliance programs can be updated to control risk going forward.

View Article

Contacts

Jones, Jaime L.M.
パートナー
Pirozzolo, Jack W.
パートナー

Related Blogs

Capabilities

Suggested News & Insights

Strictly Enforcing Rule 9(b), Second Circuit Affirms Dismissal of FCA Claim Based on Allegedly Defective Medical DevicesMarch 4, 2026
Original Source
Court Grants Motion to Dismiss FCA Claim for Failure Adequately to Plead ScienterMarch 3, 2026
Original Source
TX AG’s Office Continues Aggressive Enforcement Against Healthcare Entities Operating in TexasFebruary 25, 2026
Original Source
DAAG Brenna Jenny Warns Heightened FCA Enforcement Is “The New Normal,” Addresses Enforcement Priorities and PoliciesFebruary 20, 2026
Original Source
DAAG Jenny Reinforces Commitment to FCA Enforcement Premised on “Unlawful DEI”February 20, 2026
Original Source
DOJ Attorneys Underscore Heightened Focus on Trade Fraud During the Annual Qui Tam ConferenceFebruary 19, 2026
Original Source